1-Heptyl-4-hydroxypiperidine | 264229-47-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Heptyl-4-hydroxypiperidine
• 英文别名: 1-Heptylpiperidin-4-ol
• CAS: 264229-47-2
• 化学式: C₁₂H₂₅NO
• 分子量: 199.337
• InChiKey: IOFSVTTVKILGAE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-羟基哌啶 、 1-碘庚烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 1-Heptyl-4-hydroxypiperidine
  参考文献：
  名称：

  Quinoline derivatives and their use as antibacterial agents

  摘要：

  哌啶衍生物及其药用衍生物在哺乳动物，特别是人类的细菌感染治疗方法中有用。

  公开号：

  US06602882B1

文献信息

• Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof
  申请人：Sanofi

  公开号：US10736904B2

  公开（公告）日：2020-08-11

  The present invention relates to compounds of formula (I): wherein R6 is —CONH2 or a —C(Rα)(Rβ)(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group. Process for the preparation thereof and therapeutic use thereof.

  本发明涉及式（I）化合物： 其中 R6 是-CONH2 或-C(Rα)(Rβ)(OH)基团；R 是取代的苯基或杂芳基；R7 是任选取代的芳基或杂芳基。 其制备工艺及其治疗用途。
• Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
  申请人：Unity Biotechnology

  公开号：US10738042B2

  公开（公告）日：2020-08-11

  This disclosure provides compounds with Bcl inhibitory activity based on a new chemical scaffold, as shown in Formula (I): Phosphonamidate compounds disclosed herein typically include a P-phenyl phosphonamidate moiety which is substituted with an N-aryl or N-heteroaryl group. The P-phenyl phosphonamidate moiety may be optionally substituted at phosphorus with thio (═S) instead of oxo (═O), and/or with a thioxy group or a second amino group instead of an oxy group. One of the heteroatoms attached to phosphorus may be cyclically linked to the N-substituted nitrogen atom that is attached to the phosphorus to provide a heterocyclic ring. By incorporating such a cyclic constraint between two phosphorus substituents of the core linking moiety, a favorable binding conformation may be promoted in the compounds. Selected compounds promote apoptosis in senescent cells, and can be developed for treating senescent-related conditions, such as osteoarthritis, ophthalmic disease, pulmonary disease, and atherosclerosis. Selected compounds promote apoptosis in cancer cells, and can be developed as chemotherapeutic agents.

  本公开提供了基于新化学支架的具有 Bcl 抑制活性的化合物，如式 (I) 所示： 本文公开的膦酰胺化合物通常包括一个被 N-芳基或 N-杂芳基取代的 P-苯基膦酰胺分子。P-苯基膦甲酰胺基团可任选被硫代（═S）取代氧代（═O），和/或被硫氧基团或第二氨基取代氧基团。与磷相连的杂原子之一可与与磷相连的 N-取代的氮原子环状连接，形成杂环。通过在核心连接分子的两个磷取代基之间加入这种环状约束，可促进化合物形成有利的结合构象。所选化合物可促进衰老细胞的凋亡，并可开发用于治疗与衰老有关的疾病，如骨关节炎、眼科疾病、肺部疾病和动脉粥样硬化。精选化合物能促进癌细胞凋亡，可开发为化疗药物。
• Aryldiazepine derivatives as RSV inhibitors
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US10752598B2

  公开（公告）日：2020-08-25

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式（I）化合物及其药学上可接受的盐、酯或原药： 它们可抑制呼吸道合胞病毒（RSV）。本发明进一步涉及包含上述化合物的药物组合物，用于给受 RSV 感染的患者用药。本发明还涉及通过施用包含本发明化合物的药物组合物治疗受试者 RSV 感染的方法。
• QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1121355A1

  公开（公告）日：2001-08-08
• Phosphonamidates that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated By Senescent Cells and for Treating Cancer
  申请人：Unity Biotechnology

  公开号：US20190330199A1

  公开（公告）日：2019-10-31

  This disclosure provides compounds with Bcl inhibitory activity based on a new chemical scaffold. Phosphonamidate compounds typically include a P-phenyl phosphonamidate moiety which is substituted with an N-aryl or N-heteroaryl group. The P-phenyl phosphonamidate moiety may be optionally substituted at phosphorus with thio (═S) instead of oxo (═O), and/or with a thioxy group or a second amino group instead of an oxy group. One of the heteroatoms attached to phosphorus may be cyclically linked to the N-substituted nitrogen atom that is attached to the phosphorus to provide a heterocyclic ring. By incorporating such a cyclic constraint between two phosphorus substituents of the core linking moiety, a favorable binding conformation may be promoted in the compounds. Selected compounds promote apoptosis in senescent cells, and can be developed for treating senescent-related conditions, such as osteoarthritis, ophthalmic disease, pulmonary disease, and atherosclerosis. Selected compounds promote apoptosis in cancer cells, and can be developed as chemotherapeutic agents.